NEWARK, CA -- (Marketwired) -- 01/24/14 -- CymaBay Therapeutics, Inc. (OTCBB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs, today announced that its common stock has been cleared for quotation on the OTC Bulletin Board (OTCBB) and the OTC Market Group's OTC Link quotation system under the ticker symbol "CYMA."
CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.
For additional information about CymaBay visit www.cymabay.com.
Source: CymaBay Therapeutics